6.6
View the full transcript and gain access to JoVE Core videos
Q1: What are the main carrier systems involved in active tubular secretion?
Active tubular secretion uses three primary carrier systems: the organic anion transporter (OAT) for weak acids, the organic cation transporter (OCT) for weak bases, and ATP-powered carriers like multidrug resistance protein 4 (MRP4) and P-glycoprotein. These transporters actively move unfiltered drugs from the blood into the tubular lumen, ensuring efficient drug elimination beyond what glomerular filtration alone achieves.
Q2: How does renal plasma flow affect the rate of tubular secretion?
The rate of active tubular secretion is directly dependent on renal plasma flow (RPF). Higher renal plasma flow increases the amount of drug-containing blood delivered to the peritubular capillaries, allowing more drug molecules to be secreted into the tubular lumen. This relationship is fundamental to understanding how kidney function influences drug elimination rates.
Q3: Why do drugs like penicillin have short half-lives despite being highly protein-bound?
Penicillin and similar drugs undergo rapid elimination through active tubular secretion, which is minimally affected by drug-protein binding. Because these drugs are actively transported into the tubular lumen by carrier systems, protein binding does not significantly impede their removal from the body. This allows highly protein-bound drugs to maintain short elimination half-lives when secretion is the primary excretion route.
Q4: What do p-aminohippuric acid and iodopyracet reveal about kidney function?
P-aminohippuric acid (PAH) and iodopyracet are filtered by glomeruli and rapidly secreted by tubular cells, undergoing complete elimination in a single pass through the kidney. Their clearance reflects effective renal plasma flow (ERPF), which ranges from 425 to 650 mL/min. These drugs serve as clinical markers to assess the kidney's capacity for active secretion and overall renal function.
Q5: How can structurally similar drugs interact at renal transporters?
Structurally similar drugs compete for the same transporter systems, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. Probenecid inhibits active tubular secretion of organic acids, increasing their plasma concentration and is beneficial in treating gout by suppressing uric acid reabsorption.
Q6: What is the relationship between effective renal plasma flow and drug clearance?
Effective renal plasma flow (ERPF) is determined by renal plasma flow and the fraction of drug effectively extracted by the kidney relative to the concentration in the renal artery. ERPF typically ranges from 425 to 650 mL/min and serves as a measure of the kidney's capacity to eliminate drugs through active secretion. Understanding ERPF helps predict how efficiently a drug will be cleared.
Q7: How does the location of drug secretion differ from glomerular filtration?
While glomerular filtration occurs at the glomerulus, active tubular secretion takes place in the peritubular capillary plexus surrounding the proximal tubule. Blood exits the glomerulus via efferent arterioles and reaches this capillary network, where unfiltered drugs are actively transported into the tubular lumen by carrier systems, providing an additional elimination pathway independent of filtration.
Explore Related Chapters






